Mechanisms of cardioprotection by estrogens

Proceedings of the Society for Experimental Biology and Medicine

Volumn 217, Issue 1, 1998, Pages 23-29

  Subbiah, M T Ravi ^a,b  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN;

ANTIOXIDANT ACTIVITY; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CONFERENCE PAPER; DNA DAMAGE; ESTROGEN ACTIVITY; ESTROGEN THERAPY; FEMALE; HEART PROTECTION; HUMAN;

EID: 0031983511     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.3181/00379727-217-44201     Document Type: Conference Paper

References (83)

1. Cauley JA, Cummings SR, Blade DM, et al. Prevalence and determinants of estrogen replacement therapy in elderly women. Am J Obstet Gynecol 163:1438-1444, 1990.
2. Hammond CB, Maxson WS. Current status of estrogen therapy for menopause. Fertil Steril 37:5-25, 1982.
3. Hutchinson TA, Polansky SM, Feinstein AD. Post menopausal estrogens protect against fracture of hip and distal radius. Lancet 2:705, 1979.
4. Ross RK, Paganini-Hill A, Gerkins V, et al. A case controlled study of menopausal estrogen therapy and breast cancer. Lancet 1:858-860, 1980.
5. Lindsay R. The menopause and osteoporosis. Obstet Gynecol 87(Supplement):16S-19S, 1996.
6. Bhavnani BR. The saga of ring B unsaturated equine estrogens. Endocr Rev 9:396-416, 1988.
7. Pillai GK, McErlane KM. Quantitative determination of conjugated estrogens in formulation by capillary GLC. J Pharm Sci 70:1072-1075, 1981.
8. Adams WP, Hasegawa J, Johnson RN, and Havins RD. Conjugated estrogens bioinequivalence: Comparison of four products in postmenopausal women. J Pharm Sci 68:986-991, 1977.
9. Bhavnani BR, Wollever CA, Benoit H, Wong T. Pharmacokinetics of equilin and equilin sulphate in normal postmenopausal women and men. J Clin Endocrinol Metab 56:1048-1056, 1983.
10. Bhavnani BR, Cerutti A. Pharmacokinetics of dihydroequilin sulphate and 17β-dihydroequilin in normal postmenopausal women. J Clin Endocrinol Metab 78:197-204, 1994.
11. 3] 17β-dihydroequilin sulphate in normal postmenopausal women. Steroids 59:389-394, 1994.
12. Stern MD. Pharmacology of conjugated estrogen. Maturitas 4:333-339, 1982.
13. Bhavnani BR, Woolever CA. Interaction of ring B unsaturated estrogens with estrogen receptors of human endometrium and rat uterus. Steroids 56:201-209, 1991.
14. Howard KP, Keaty EC. Evaluation of equilin 3-monosulphate and other estrogens. Ann Intern Med 128:224-234, 1978.
15. Anderson AB, Sklovsky E, Sayers L, Steel PA, Tumbull AC. Comparison of estrogen concentration in postmenopausal women taking oestrone sulphate and estradiol. Biochem J 1:140-142, 1978.
16. Stevens RL, Flutarty AL, Killgrove AR, Kihara H. Aryl sulphates of human tissue: Studies on a form of aryl sulphate B found predominantly in the brain. Biochim Biophys Acta 481:549-550, 1977.
17. Bush TL. The epidemiology of cardiovascular disease in postmenopausal women. Ann NY Acad Sci 592:263-271, 1990.
18. Lobo RA. Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab 73:925, 1991.
19. Lobo RA. Cardiovascular implications of estrogen replacement therapy. Obstet Gynecol 75:18S, 1990.
20. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses Health Study. N Engl J Med 325:756-762, 1991.
21. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 256:1861, 1991.
22. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Prev Med 20:47, 1991.
23. Seed M. Sex hormones, lipoproteins, and cardiovascular risk. Atherosclerosis 90:1-7, 1991.
24. The Writing Group for the PEPI Trial. Effect of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women. JAMA 273:199-208, 1995.
25. Paganini-Hill A, Dworsky R, Krauss RM. Hormone replacement therapy, hormone levels, and lipoprotein cholesterol concentration in elderly women. Obstet Gynecol 174:897-902, 1996.
26. Parish E, Spowart K, Barnes JF, Fletcher CD, Hart PM, Dagen MM. Effects of postmenopausal hormone replacement therapy on lipoproteins including lipoprotein(a) and LDL subfractions. Atherosclerosis 126:77-84, 1996.
27. Lahdenpara S, Puolakka J, Pyorala T, Luotola H, Taskinen MR. Effects of postmenopausal estrogen/progestin replacement therapy on LDL particles: Comparison of transdermal and oral treatment regimens. Atherosclerosis 122:153-162, 1996.
28. Miller VT, Muesing RA, LaRosa JC, Phillips EA, Stillman RJ. Effects of conjugated estrogen with and without three different progestogens on lipoproteins, high density lipoprotein subfractions, and apolipoprotein AI. Obstet Gynecol 77:235-240, 1991.
29. Soma MR, Oswago I, Paoletti R, Fumagalli R, Morriset JD, Moschia M, Crosignani P. The lowering of lipoprotein(a) induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch Intern Med 153:1402-1408, 1993.
30. Ottosson U, Johansson B, Von Schoultz B. Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: A comparison between progestogens and natural progesterone. Am J Obstet Gynecol 151:746-750, 1985.
31. Bush TL, Barrett-Connor E, Cowan LD, Criquie MH, Wallace RB, Suchinddran CM, Tyroler HA, Rifkind BM. Cardiovascular mortality and non-contraceptive estrogen use in women: Results from the Lipid Research Clinics Program Follow-Up Study. Circulation 75:1002-1009, 1987.
32. Adams MR, Clarkson TB, Shively CA, Parks JA, Kaplan JR. Oral contraceptives, lipoproteins, and atherosclerosis. Am J Obstet Gynecol 163:1388-1393, 1990.
33. Maziere C, Auclair M, Ronveaux MC, Salmon S, Santus R, Maziere JC. Estrogen inhibits copper and cell-mediated modification of low density lipoprotein. Atherosclerosis 89:175-182, 1991.
34. Sack MN, Rader DJ, Cannon RO. Oestrogen and inhibition of oxidation of low density lipoproteins in postmenopausal women. Lancet 343:269-270, 1994.
35. Guetta V, Lush RM, Figg WD, Waclawiw MA, Cannon RO. Effect of antiestrogen tamoxifen on low density lipoprotein concentration and oxidation in postmenopausal women. J Amer Cell Cardiol 76:1072-1073, 1995.
36. Mukai K, Daifuku K, Yokoyama S, Nakano M. Stopped flow investigation of antioxidant effects of estrogen. Biochim Biophys Acta 1035:348-352, 1990.
37. Subbiah MTR, Kessel B, Agrawal M, Rajan R, Abplanalp W, Rymaszewski Z. Antioxidant potential of specific estrogens on lipid peroxidation. J Clin Endocrinol Metab 77:1095-1097, 1993.
38. Heinecke JW. Free radical modification of low density lipoproteins: Mechanism and biological consequences. Free Radic Biol Med 3:65-73, 1991.
39. Arshad MAQ, Bhadra S, Cohen RM, Subbiah MTR. Plasma lipoprotein peroxidation potential: A method to determine individual susceptibility to peroxidation. Clin Chem 37:1756-1758, 1991.
40. Rifici VA, Khachadurian AK. The inhibition of low-density lipoprotein oxidation by 17-β estradiol. Metabolism 41:1110-1114, 1992.
41. Zumoff B. Biological and endocrinological insights into the possible breast cancer risk from menopausal estrogen replacement therapy. Steroids 58:196, 1993.
42. Nelson DR, Kawataki F, Waxman DH, Guengerich FP, Estabrook RW, Feyereisen R, Gonzalez FJ, Coon MJ, Garsulus IC, Gotoh O, Okuda K, Nebert DW. The P-450 superfamily: Update on new sequence, gene mapping, accession numbers, early trivial names, and nomenclature. DNA Cell Biol 12:1, 1993.
43. Ashtroff B, Rowlands C, Dickerson R, Safe S. 2378 tetrachlorodibenzo-p-dioxin inhibition of estradiol-17β induced increases in rat uterine epidermal growth factor receptor binding activity and gene expression. Mol Cell Endocrinol 72:247, 1990.
44. Spink D-C, Lincoln DW, Dickermann HW, Gierthy GF. 2378 tetrachlorodibenzo-p-dioxin causes an extensive alteration of 17β-estradiol metabolism in MCF-7 breast tumor cells. Proc Natl Acad Sci USA 87:6917, 1990.
45. MacMahan B, Trichopoulos D, Cole P. Cigarette smoking and urinary estrogens. N Engl J Med 307:1062, 1982.
46. Schneider J, Sasia S, Kappas A. Metabolism of estradiol in liver cell culture: Differential references of C-2 and C-16 oxidations to drugs and other chemicals that induce selective species of cytochrome P-450. J Clin Invest 72:1420, 1983.
47. Michnovicz JJ, Hershcopf RJ, Naganuma H, Bradlow HL, Fishman J. Increased 2-hydroxylation of estradiol as a possible mechanism for the autoestrogen effect of cigarette smoking. N Engl J Med 315:1305, 1986.
48. Tang M, Abplanalp W. Ayres S, Subbiah MTR. Superior and distinct antioxidant properties of selected estrogen metabolites on lipid peroxidation. Metabolism 45:411-414, 1996.
49. Ayres S, Tang M, Subbiah MTR. Estradiol-17β as an antioxidant: Some distinct features when compared to fat soluble vitamins. J Lab Clin Med 128:367-375, 1996.
50. Tang M, Subbiah MTR. Estrogens protect against hydrogen peroxide and arachidonic acid induced DNA damage. Biochim Biophys Acta 1299:155-159, 1996.
51. Applebaum-Bowden D, McLean P, Steinmetz A, Fontana D, Matthys C, Warnick GR, Albers JJ, Hazzard WR. Lipoprotein, apoprotein, and lipolytic enzyme changes following estrogen administration. J Lipid Res 30:1895, 1989.
52. Leuven JG. Sex steroids and lipoprotein metabolism. Pharmacol Ther 64:99-126, 1994.
53. Anderson D. Sex hormone binding globulin. Clin Endocrinol 3:69-96, 1974.
54. Rao GS. Mode of entry of steroid and thyroid hormones into cells. Mol Cell Endocrinol 21:97-108, 1981.
55. Leszczynski DE, Schafer RM. Characterization of steroid hormone association with human plasma lipoproteins. Steroids 54:37-53, 1989.
56. Leszczynski DE, Schafer RM. Metabolic conversion of six steroid hormones by human plasma high density lipoprotein. Biochim Biophys Acta 1083:18-28, 1991.
57. Janucko L, Hochberg RB. Estradiol fatty acid esters occur naturally in human blood. Science 222:1334-1336, 1983.
58. Tang M, Abplanalp W, Subbiah MTR. Association of estrogens with human plasma lipoproteins: Studies with estradiol-17β and its hydrophobic derivative. J Lab Clin Med 129:447-452, 1997.
59. Jiang C, Sarrel PM, Lindsay D, Poole-Wilson PA, Collins P. Acute effects of 17β-estradiol on rabbit coronary artery contractile response to endothelin-a. Am J Physiol 263H-271-H275, 1992.
60. Williams JK, Adams MR, Herrington DM, Clarkson TB. Short-term administration of estrogens and vascular response of atherosclerotic coronary arteries. J Am Coll Cardiol 20:452-457, 1992.
61. Rees SE, Gluth ST, Blumenthal RS, Resar JR, Zacar HA, Gerstenblith G, Brinker JA. Ethynyl estradiol acutely attenuates abnormal coronary vasomotor response to acetylcholine in postmenopausal women. Circulation 89:52-60, 1994.
62. Rosano GMC, Sarrel RM, Poole-Wilson PA, Collins D. Beneficial effect of oestrogen on exercise induced myocardial ischemia in women with coronary artery disease. Lancet 362:133-136, 1993.
63. Collins P, Giuseppe MC, Rosano MC, Sarrel PM, Ulrich L, Adamopoulous S, Beale CM, McNeill JG, Poole-Wilson PA. 17β-Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 92:24-30, 1995.
64. Van Buren G, Yang D, Clark KE. Estrogen induced uterine vasodilitation is antagonized by L-nitro organism methylester, an inhibitor of nitric-oxide synthesis. Am J Obstet Gynecol 16:828-833, 1992.
65. Weiner CP, Lizasoain I, Baylis SA, Knowles RG, Charles IG, Mancada S. Induction of calcium dependent nitric oxide synthesis by sex hormones. Proc Natl Acad Sci USA 91:5212-5216, 1994.
66. Farhat MY, Lavigne MC, Ramwell PW. The vascular protective effect of estrogen. FASEB J 10:615-624, 1996.
67. Hoover K. Menopausal estrogens and breast cancer. N Engl J Med 295:401-405, 1976.
68. Li JJ and Li SA. Estrogen carcinogenesis in hamster tissues: A critical review. Endocrine Rev 11:524-531, 1990.
69. Key TJA, Pike MC. The role of oestradiol and progestins in epidemiology and prevalence of breast cancer. Eur J Cancer Clin Oncol 24:29-43, 1989.
70. Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zak MM, Flanders WD, Berkelman RL. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 265:1985-1990, 1991.
71. Dupont WD, Page DL. Therapy and breast cancer. Arch Intern Med 151:67-72, 1991.
72. Armstrong BK. Oestrogen therapy after the menopause - boon or bane? Med J Aust 148:213-219, 1988.
73. Grady D, Ernster V. Does post menopausal hormone therapy cause breast cancer? Am J Epidemiol 134:1390-1400, 1991.
74. Colditz GA, Stampfer MJ, Willett WC, Hennekens CH, Rosner B, Speizer F. Prospective study of estrogen replacement therapy and the risk of breast cancer in post menopausal women. JAMA 264:2648-2653, 1990.
75. The Writing Group for the PEPI Trial. Effect of hormone replacement therapy on endometrial histology in postmenopausal women. JAMA 275:370-375, 1996.
76. Osborne MD, Bradlow HC, Wong GYC, Telang NT. Upregulation of estradiol P-16α hydroxylation in human breast tissue: A potential biomarker of breast cancer risk. J Natl Cancer Inst 85:1917, 1993.
77. Telang NJ, Sato A, Wang GY. Induction of estrogen metabolite 16α-hydroxy estrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. J Natl Cancer Inst 84:636, 1992.
78. Vanderwalle P, Peyrat JP, Bonneterre J, Lefebvre J. Catechol binding sites in breast cancer. J Steroid Biochem Mol Biol 23:603, 1985.
79. Liehr JG. Genotoxic effects of estrogen. Mutat Res 238:269, 1990.
80. Vanderwalle P, Lefebvre J. Opposite effects of estrogen and catechol estrogens on hormone sensitive breast cancer cell line growth and differentiation. Mol Cell Endocrinol 61:239, 1989.
81. Li Y, Trush MA, Yager JD. DNA damage caused by reactive oxygen species originating from a copper dependent oxidation of 2-hydroxy catechol of estradiol. Carcinogenesis 15:1421-1427, 1994.
82. Speroff L. Postmenopausal hormone therapy and breast cancer. Obstet Gynecol 87:448-545, 1996.
83. Kaufmann RF, Bryant HV. Selective estrogen receptor modulators. Drugs 8:531-539, 1995.